Quarterly report pursuant to Section 13 or 15(d)

Business and Liquidity (Details)

v2.4.0.6
Business and Liquidity (Details) (USD $)
3 Months Ended 6 Months Ended 1 Months Ended
Jun. 30, 2012
Jun. 30, 2011
Jun. 30, 2012
item
segment
Jun. 30, 2011
Dec. 31, 2011
Feb. 22, 2011
Convertible Notes
Jul. 31, 2012
Subsequent Event
Convertible Notes
Second tranche
Business and Liquidity              
Period since the entity has begun commercialization outside the United States of its newest product, RenalGuard     4 years        
Number of operating segments     1        
Loss from continuing operations $ 1,444,000 $ 541,000 $ 8,222,000 $ 5,560,000      
Cash used in operations     1,464,000 2,122,000      
Accumulated deficit 106,949,000   106,949,000   98,727,000    
Number of independent investigator-sponsored clinical trials     2        
Additional capital raised              
Additional capital raised through the completion of additional financing by the closing on the second tranche of convertible notes           $ 4,000,000 $ 1,000,000